
The wholly-owned subsidiary has received approval from Japan#39;s Ministry of Health, Labour and Welfare for Ilumya (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies, Sun Pharmaceutical Industries said in filing to BSE.
from Moneycontrol Business News https://ift.tt/3dJWFPB
No comments:
Post a Comment